3.60

13.25% -0.55

After Hours: 3.39 -0.21 -5.83%

Citius Pharmaceuticals Inc (CTXR)

Overview News Price History Option Chain Financials Why CTXR Down? Discussions Forecast Stock Split

Citius Pharmaceuticals Inc stock is traded at $3.60, with a volume of 415.69K. It is down -13.25% in the last 24 hours and down -60.44% over the past month. Citius Pharmaceuticals Inc is a biopharmaceutical company with a focus on anti-infectives in adjunct cancer care, prescription products, and stem cell therapy. It is currently advancing four proprietary product candidates: LYMPHIR for the treatment of patients with persistent or recurrent cutaneous T-cell lymphoma . Mino-Lok, which is an antibiotic lock solution used to treat patients with catheter-related bloodstream infections; Mino-Wrap, a liquifying gel-based wrap for reduction of tissue expander infections following breast reconstructive surgeries; Halo-Lido, a topical formulation that is intended to provide anti-inflammatory and anesthetic relief to persons suffering from hemorrhoids; NoveCite, a mesenchymal stem cell therapy for the treatment of acute respiratory distress syndrome.

Previous Close:

$4.15

Open:

$3.6

24h Volume:

415.69K

Relative Volume:

2.17

Market Cap:

$29.28M

Revenue:

Net Income/Loss:

$-32.54M

P/E Ratio:

-18.00

EPS:

-0.2

Net Cash Flow:

$-29.06M

1W Performance:

-15.24%

1M Performance:

-60.44%

6M Performance:

-78.18%

1Y Performance:

-81.57%

1-Day Range:

$3.50

$4.1094

1-Week Range:

$2.55

$4.61

52-Week Range:

$2.55

$26.75

Citius Pharmaceuticals Inc Stock (CTXR) Company Profile

Name

Citius Pharmaceuticals Inc

Sector

Healthcare (1200)

Industry

Biotechnology (682)

Phone

(908) 967-6676

Address

11 COMMERCE DRIVE, CRANFORD, NJ

Employee

Twitter

Next Earnings Date

2024-08-12

Latest SEC Filings

CTXR's Discussions on Twitter

Compare CTXR with other stocks

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
CTXR Citius Pharmaceuticals Inc	3.60	29.28M	0	-32.54M	-29.06M	-0.20
VRTX Vertex Pharmaceuticals Inc	464.56	119.70B	10.63B	-479.80M	-1.35B	13.33
REGN Regeneron Pharmaceuticals Inc	754.87	82.75B	13.85B	4.65B	3.32B	35.06
ARGX Argen X Se Adr	614.59	36.73B	1.86B	-40.29M	-1.28B	-4.16
ALNY Alnylam Pharmaceuticals Inc	253.74	32.53B	2.09B	-332.26M	16.06M	-4.14
BNTX Biontech Se Adr	120.72	28.50B	3.30B	-501.07M	1.03B	11.54

Citius Pharmaceuticals Inc Stock (CTXR) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Nov-30-21	Initiated	Maxim Group	Buy

Citius Pharmaceuticals Inc Stock (CTXR) Latest News

Nov 27, 2024

Hemorrhoids Market Expected to Experience Major Growth by 2032, - openPR

Nov 27, 2024

Nov 26, 2024

Citius Pharmaceuticals, Inc. Holds Pre-BLA Meeting with the FDA for I/ONTAK for the Treatment of Cutaneous T-Cell Lymphoma - Marketscreener.com

Nov 26, 2024

Citius Pharmaceuticals to Present at the LD Micro Invitational XIV Investor Conference - Marketscreener.com

Nov 26, 2024

Citius Pharmaceuticals to Host Investor Call to Discuss Topline Results of Phase 3 Trial of Mino-Lok Antibiotic Lock Solution - Marketscreener.com

Nov 26, 2024

Citius Pharmaceuticals, Inc. Appoints Jaime Bartushak as the Chief Financial Officer and Principal Financial Officer - Marketscreener.com

Nov 26, 2024

Citius Pharmaceuticals to Participate in the Sidoti Micro-Cap Virtual Conference on November 15, 2023 - Marketscreener.com

Nov 26, 2024

Citius Pharmaceuticals Engages Financial Advisor for Oncology Subsidiary Spinoff - Marketscreener.com

Nov 26, 2024

Citius Pharmaceuticals to Host Investor Call to Discuss Recent and Upcoming Developments - Marketscreener.com

Nov 26, 2024

Citius Pharmaceuticals Inc. filed SEC Form 8-K: Material Modification to Rights of Security Holders, Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Other Events, Financial Statements and Exhibits - Quantisnow

Nov 26, 2024

Citius Pharma progresses with FDA on Mino-Lok approval By Investing.com - Investing.com Nigeria

Nov 26, 2024

Citius Pharmaceuticals (NASDAQ:CTXR) Earns Hold Rating from D. Boral Capital - Defense World

Nov 26, 2024

Nov 25, 2024

Citius Pharma progresses with FDA on Mino-Lok approval - Investing.com India

Nov 25, 2024

Citius Pharmaceuticals Reports Productive FDA Type C Meeting to Discuss Phase 3 Mino-Lok® Program and Pathway to Approval - PR Newswire

Nov 25, 2024

Nov 24, 2024

Citius Pharmaceuticals Stock Set to Reverse Split on Tuesday, November 26th (NASDAQ:CTXR) - Defense World

Nov 24, 2024

Nov 22, 2024

Citius Pharmaceuticals Announces 1-for-25 Reverse Stock Split - citybiz

Nov 22, 2024

Citius Pharmaceuticals announces 1-for-25 reverse stock split - MSN

Nov 22, 2024

Citius Pharmaceuticals Announces 1-for-25 Reverse Stock Split to Maintain Nasdaq Listing | CTXR Stock News - StockTitan

Nov 22, 2024

Citius Pharmaceuticals stock hits 52-week low at $0.16 By Investing.com - Investing.com Australia

Nov 22, 2024

Nov 21, 2024

Citius Pharmaceuticals stock hits 52-week low at $0.16 - Investing.com India

Nov 21, 2024

Nov 20, 2024

Citius Pharmaceuticals reports positive early stage results of cancer combo treatment - MSN

Nov 20, 2024

Nov 19, 2024

Citius Pharmaceuticals, Inc. (NASDAQ:CTXR) Short Interest Update - Defense World

Nov 19, 2024

Citius Pharmaceuticals (NASDAQ: CTXR) Announces Successful Closure of Offering - Defense World

Nov 19, 2024

Citius Pharmaceuticals Announces Closing of $3 Million Registered Direct Offering - BioSpace

Nov 19, 2024

Nov 18, 2024

Citius Pharmaceuticals Raises $3M in Direct Offering at $0.25 Per Share with Warrants | CTXR Stock News - StockTitan

Nov 18, 2024

Nov 15, 2024

Citius Pharmaceuticals Announces $3 Million Registered Direct Offering - The Malaysian Reserve

Nov 15, 2024

Citius Pharmaceuticals Raises $3M in Direct Offering at $0.25 Per Share | CTXR Stock News - StockTitan

Nov 15, 2024

What is HC Wainwright’s Estimate for CTXR FY2024 Earnings? - Defense World

Nov 15, 2024

Nov 14, 2024

Citius Pharmaceuticals stock hits 52-week low at $0.31 By Investing.com - Investing.com South Africa

Nov 14, 2024

Citius Pharmaceuticals granted extension to regain Nasdaq compliance - Investing.com

Nov 13, 2024

Citius Pharmaceuticals granted extension to regain Nasdaq compliance By Investing.com - Investing.com Australia

Nov 13, 2024

Q1 Earnings Forecast for CTXR Issued By HC Wainwright - MarketBeat

Nov 13, 2024

Nov 12, 2024

Citius Pharmaceuticals (NASDAQ:CTXR) Receives Buy Rating from HC Wainwright - MarketBeat

Nov 12, 2024

Nov 11, 2024

Citius Pharmaceuticals, Inc. and Citius Oncology, Inc. Announce Promising Preliminary Results of an Investigator-Initiated Phase I Clinical Trial of Pembrolizumab (KEYTRUDA®) and LYMPHIR™ in Cancer Patients with Recurrent Solid Tumors - The Malaysian Reserve

Nov 11, 2024

Citius' LYMPHIR Shows Potential To Boost Pembrolizumab Efficacy - Contract Pharma

Nov 11, 2024

Citius Pharmaceuticals, Inc. and Citius Oncology, Inc. Announce Promising Preliminary Results of an Investigator-Initiated Phase I Clinical Trial of Pembrolizumab (KEYTRUDA®) and LYMPHIR™ in Cancer Patients with Recurrent Solid Tumors – Company An - Financial Times

Nov 11, 2024

Nov 06, 2024

Citius Pharmaceuticals stock hits 52-week low at $0.32 - Investing.com India

Nov 06, 2024

Citius Pharmaceuticals stock hits 52-week low at $0.32 By Investing.com - Investing.com UK

Nov 06, 2024

Citius Pharmaceuticals, Inc. (NASDAQ:CTXR): Is Breakeven Near? - Simply Wall St

Nov 06, 2024

Oct 24, 2024

Citius Pharmaceuticals stock hits 52-week low at $0.34 By Investing.com - Investing.com Australia

Oct 24, 2024

Citius Pharmaceuticals stock hits 52-week low at $0.34 - Investing.com India

Oct 24, 2024

Oct 17, 2024

CTXR (Citius Pharmaceuticals) Cyclically Adjusted Revenue p - GuruFocus.com

Oct 17, 2024

Oct 15, 2024

Investing in Citius Pharmaceuticals Inc (CTXR) might be a great opportunity, but the stock is a bit undervalued - US Post News

Oct 15, 2024

Oct 14, 2024